Loading clinical trials...

Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

Prospective, Randomized Comparison of Corticosteroid Dosing Regimens Following Endothelial Keratoplasty

NCT01853696•Cornea Research Foundation of America

Summary

Graft rejection has traditionally been one of the leading causes of cornea transplant failure. To help prevent rejection, corticosteroid eye drops are used for an extended period after transplant surgery. The purpose of this study is to compare the efficacy and side effects of different corticosteroid dosing regimens after endothelial keratoplasty (cornea transplant) surgery.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•At least 18 years of age
•Male or female patient who had endothelial keratoplasty procedure within the past 1 to 7 weeks
•Patient is able and willing to administer eye drops
•Patient is able to comprehend and has signed the Informed Consent form.
•Patient is likely to complete the one-year course of the study

Exclusion Criteria

•A history of a previous rejection episode in the study eye
•A patient exhibiting intraocular inflammation
•A patient with a known sensitivity to any of the ingredients in the study medications
•A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study
•A patient with abnormal eyelid function.
•A patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis.
•Presence of any ocular disease that would interfere with the evaluation of the study treatment. However, patients with a history of cystoid macular edema, age-related macular degeneration, controlled glaucoma, corneal neovascularization, and other non-interfering comorbidities may be enrolled.
•A patient with a history of non-compliance with using prescribed medication.
•A patient who is concurrently involved in or participated in another randomized clinical trial within 30 days prior to enrollment in this study.
•Patients who are pregnant or planning to become pregnant within the duration of the study

Locations (1)

Price Vision Group

Indianapolis, Indiana, United States

Key Dates

Start Date

March 1, 2013

Primary Completion Date

January 1, 2015

Completion Date

January 1, 2015

Last Updated

May 15, 2015

Enrollment

167

ACTUAL participants

Conditions

Fuchs' DystrophyCorneal Edema

Interventions

loteprednol etabonate

DRUG

prednisolone acetate 1%

DRUG

The Belgian Endothelial Surgical Transplant of the Cornea

NCT05436665

Corneal EdemaCorneal Endothelial Disorder+3 more

View study

RECRUITING

Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema

NCT06983652

Corneal DiseasesCorneal Scars and Opacities+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 15, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

Inclusion Criteria

Exclusion Criteria

The Belgian Endothelial Surgical Transplant of the Cornea

Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

EndoArt® Implantation in Subjects With Chronic Corneal Edema

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy